CD137 agonist antibodies and uses thereof

Inventors

Kurtzman, Aaron • Tran, Hieu • Chen, Shihao

Assignees

QLSF Biotherapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12227582-B2

Patent

Publication Date

2025-02-18

Expiration Date


Abstract

The present disclosure provides isolated binding molecules that bind to and activates CD137, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.

Core Innovation

The invention provides isolated monoclonal antibodies and antigen-binding portions that agonize human CD137 (4-1BB/TNFRSF9). The antibodies specifically bind human CD137 and are defined by heavy chain variable region CDR1, CDR2, and CDR3 sequences and light chain variable region CDR1, CDR2, and CDR3 sequences. The described CDRs are provided as specific SEQ ID NOs, including embodiments with defined sequence-identity options for corresponding CDR sequence sets.

In addition to the defined CDR sequence compositions, the invention encompasses antibody-associated formats and materials, including pharmaceutical compositions and immunoconjugates. The disclosed antibody formats include antibody fragments and variations, together with associated nucleic acid vectors and host cells. The disclosure further supports activation and functionality through Fc-dependent effects, including NF-κB reporter activation described as CD137 pathway signaling readouts.

The disclosure includes functional and experimental data showing that the antibodies bind human and cynomolgus 4-1BB and induce CD137 agonist activity. The described activity includes NF-κB reporter activation that is dependent on Fc cross-linking, as well as T cell proliferation and IFN-γ secretion in co-culture assays. Therapeutic activity is also supported by anti-4-1BB-mediated tumor growth inhibition in hu4-1BB knock-in MC38 colon cancer mice with reported tumor-free outcomes and no drug-related toxicity at the tested doses.

Claims Coverage

The partial content includes two independent claim sets that provide CD137 agonist specificity defined by either specific heavy- and light-chain CDR sequences and human CD137 binding, or membership in specified sets of light- and heavy-chain amino-acid sequences. Across these independent claims, there are key sequence-definition constraints that delimit the antibody variable regions and their antigen-binding specificity, with additional claim coverage indicated by the listed dependent claims for formats, identity thresholds, immunoconjugates, and therapeutic or indication uses.

Cdr-defined human CD137 agonist antibody binding

An isolated anti-CD137 agonist antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region CDR1 comprising SEQ ID NO:29, a heavy chain variable region CDR2 comprising SEQ ID NO:30, and a heavy chain variable region CDR3 comprising SEQ ID NO:31; and a light chain variable region CDR1 comprising SEQ ID NO:26, a light chain variable region CDR2 comprising SEQ ID NO:27, and a light chain variable region CDR3 comprising SEQ ID NO:28, wherein said antibody or portion specifically binds to human CD137.

Sequence-set light-chain and heavy-chain monoclonal antibody selection

An isolated monoclonal antibody or antigen binding portion thereof, comprising a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43-46 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47-50.

Overall, the independent claims delineate CD137 agonist antibodies by defining the antigen-binding region at the sequence level, either by specific heavy/light CDR SEQ ID NO assignments for human CD137 binding, or by selection from specified light- and heavy-chain amino-acid sequence sets.

Stated Advantages

Stimulates immune responses via CD137 agonist activity, including NF-κB reporter activation.

Induces T cell proliferation and IFN-γ secretion in co-culture assays.

Provides anti-4-1BB-mediated tumor growth inhibition in hu4-1BB knock-in MC38 colon cancer mice, with reported tumor-free outcomes.

No drug-related toxicity at the tested doses is reported in the disclosed data.

Documented Applications

Stimulating immune responses in a subject by administering a pharmaceutical composition containing the claimed CD137 agonist antibody.

Treating colon cancer in a subject by administering the pharmaceutical composition containing the claimed CD137 agonist antibody.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.